Creative Life Science Co

Creative Life Science Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of Creative Life Science Co (7837.TWO) as of Nov 11, 2026 is 0.51. In the previous year, Long-Term Debt to Equity Ratio was 0.76 — a change of -33.17% (lower).

LT Debt/Equity

0.51

YoY

-33.17%

Last updated:

Long-Term Debt to Equity Ratio of Creative Life Science Co is 2024 0.51 . Long-Term Debt to Equity Ratio of Creative Life Science Co was 2023 0.76 . It decreases by -33.17% lower compared to the previous year.

The Creative Life Science Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2022
0.26 TWD
Jan 1, 2023
0.76 TWD
Jan 1, 2024
0.51 TWD
The Creative Life Science Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.51-33.17%
0.76+186.69%
0.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Creative Life Science Co Stock analysis

What does Creative Life Science Co do? Creative Life Science Co., Ltd. generates revenue through the sales of its own CMP brand products and agency services for international brands. The CMP product line includes storage and carrying culture medium, sterile transport containers, buffers and diluents, identification reagents, and various culture media types. The company acts as an agent for dry powder culture medium, detection reagents, IVD culture medium, and sampling systems. Its primary market is Taiwan, serving pharmaceutical, biotechnology, food, medical diagnosis, environmental monitoring, and academic research sectors. The company also offers testing, inspection, and certification services to complement its product sales. The firm's revenue streams are derived from direct sales of CMP products to customers in regulated industries such as pharmaceuticals and medical diagnostics. International brand agency sales target similar sectors requiring specialized culture media and diagnostic tools. Testing and certification services are provided to clients needing quality assurance in product development and compliance. All services are concentrated within Taiwan's domestic market, with no mention of international distribution channels. CMP brand products are sold to laboratories and production facilities across multiple industries including food safety testing and environmental monitoring. The agency business focuses on supplying IVD culture media and sampling systems to medical and diagnostic institutions. Testing services support clients in meeting regulatory standards for product safety and efficacy. The company's operations remain strictly within Taiwan, with no indication of global market expansion. Creative Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Creative Life Science Co stock

Long-Term Debt to Equity Ratio of Creative Life Science Co is 0.51 in 2024.

Long-Term Debt to Equity Ratio of Creative Life Science Co changed from 0.76 to 0.51, representing a -33.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Creative Life Science Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Creative Life Science Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Creative Life Science Co

All Key Metrics — Creative Life Science Co